Welcome to our dedicated page for ATRECA A news (Ticker: BCEL), a resource for investors and traders seeking the latest updates and insights on ATRECA A stock.
Atreca Inc (NASDAQ: BCEL) is a pioneering biotechnology company dedicated to the development of innovative cancer immunotherapeutics. Leveraging its unique Immune Repertoire Capture™ (IRC™) technology, Atreca has gained unparalleled insight into the human immune response. This advanced platform allows the company to identify unique antibody-target pairs generated by the immune system during an active immune response against tumors.
Atreca's core focus is on developing antibody-drug conjugates (ADCs), a promising class of therapeutics that combines the targeting capabilities of antibodies with potent anti-cancer drugs. The company’s lead program, APN-497444, targets a novel tumor glycan and exemplifies the potential of Atreca’s discovery platform to generate first-in-class oncology treatments.
Recently, Atreca has undergone a significant corporate reorganization aimed at reducing expenses and extending its cash runway. This includes suspending the development of ATRC-101, a promising therapeutic previously advanced into the clinic, and reducing its workforce by approximately 40%. The company is now concentrating its efforts on advancing preclinical ADC candidates, particularly APN-497444, while preserving its core discovery capabilities.
Atreca has also established strategic partnerships to further its mission. Notably, it has licensed MAM01/ATRC-501, a clinical candidate for malaria prevention, to the Bill & Melinda Gates Medical Research Institute. This partnership underscores Atreca’s commitment to leveraging its platform for both oncology and infectious diseases.
The company’s financial condition and strategic decisions, such as the termination of a long-term lease agreement to reduce operating expenses, reflect a careful balance of innovation and fiscal responsibility. Atreca’s leadership, including CEO John Orwin, emphasizes the importance of focusing resources on high-potential projects while exploring strategic alternatives for non-core assets.
For those interested in contributing to Atreca’s groundbreaking work, the company is actively seeking talented individuals. Open positions can be found on their careers page.
Atreca announced positive initial results from its Phase 1b trial of ATRC-101 targeting solid tumors with >50% target expression. The trial's dose escalation phase showed that ATRC-101 was well-tolerated and displayed promising disease control, particularly in patients with high target expression. A total of 26 participants were dosed, with no dose-limiting toxicities reported. Preliminary biomarker data support the proposed mechanism of action. The company is expanding the trial and developing a diagnostic for patient selection, with additional results expected in mid to late 2022.
Atreca, Inc. (NASDAQ: BCEL) announced a conference call and webcast on July 29, 2021, to present initial data from its ongoing Phase 1b trial evaluating ATRC-101 in select solid tumors. ATRC-101, a monoclonal antibody derived from Atreca's unique discovery platform, is designed to engage the innate immune system for tumor destruction. The company plans to expand clinical trials for ATRC-101 in combination therapies later in 2021. The Phase 1b study is currently enrolling patients, aiming to provide insights into efficacy and safety.
Atreca, a clinical-stage biotechnology company (NASDAQ: BCEL), has appointed Dr. Stacey Ma and Stephen R. Brady to its Board of Directors. Dr. Ma brings 23 years of experience from roles at Sana Biotechnology and Genentech/Roche, while Mr. Brady has leadership experience from Tempest Therapeutics and Immune Design Corp. Their collective expertise, spanning technical operations, research, and finance, is expected to aid Atreca in advancing its lead product candidate, ATRC-101, which is currently in a Phase 1b study for treating solid tumors.
Atreca, a biotechnology company focusing on innovative therapeutics, announced presentations at two upcoming virtual investor conferences. The Cowen Oncology Innovation Summit will take place on May 21, 2021, at 10:40 a.m. EDT, followed by the Jefferies Healthcare Conference on June 2, 2021, at 3:30 p.m. EDT. Investors can access live audio webcasts via Atreca's website, with archived replays available for 90 days. Atreca is developing antibody-based immunotherapeutics, including the lead product candidate ATRC-101, currently in Phase 1b trials for multiple solid tumors.
Atreca, Inc. (NASDAQ: BCEL) announced its financial results for Q1 2021, reporting a net loss of $25.8 million, translating to a net loss per share of $0.70. The company has $211.7 million in cash and investments as of March 31, 2021. Progress was noted in the Phase 1b trial of ATRC-101, with 20 patients enrolled. No dose-limiting toxicities were reported, and further patient enrollment is expected soon. Additionally, Atreca launched APN-122597 targeting EphA2, with plans for an R&D Day in 4Q 2021 to discuss pipeline developments.
Atreca, a biotechnology company listed on NASDAQ under the symbol BCEL, announced participation in two significant virtual investor conferences. The first is the 20th Annual Needham Virtual Healthcare Conference on April 13, 2021, at 1:30 p.m. EDT, followed by the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2021, at 4:00 p.m. EDT. Investors can access a live audio webcast of the Needham presentation on Atreca's website. The company is known for developing innovative antibody-based immunotherapeutics, including its lead candidate, ATRC-101.
Atreca, Inc. (NASDAQ: BCEL) announced a trial-in-progress poster presentation at the virtual AACR Annual Meeting, scheduled for April 10-15 and May 17-21, 2021. The poster will detail the design of a Phase 1b clinical trial assessing ATRC-101 as a monotherapy and in combination with pembrolizumab for patients with solid tumors. The full abstract will be available on the AACR website on April 9, with the poster accessible on Atreca's website starting April 10. This study highlights Atreca's innovative approach in developing antibody-based immunotherapeutics derived from the human immune response.
Atreca, Inc. (NASDAQ: BCEL) announced its 2020 financial results, marking a year of significant progress. The company initiated its first-in-human study of ATRC-101 and secured multiple strategic collaborations. As of December 31, 2020, Atreca reported $240.1 million in cash and short-term investments. Research and development expenses reached $62.0 million, while general and administrative expenses amounted to $26.8 million. The company recorded a net loss of $86.3 million for the year, with a loss per share of $2.70. Upcoming milestones include initial data from the Phase 1b trial in 2Q 2021.
Atreca, Inc. (NASDAQ: BCEL), a clinical-stage biotechnology firm, will participate in several virtual investor conferences in March 2021. The schedule includes the Cowen 41st Annual Health Care Conference on March 1 at 1:20 p.m. EST discussing "Novel Oncology Targets," the H.C. Wainwright Global Life Sciences Conference on March 9 at 7:00 a.m. EST, and the 33rd Annual Roth Conference on March 16 at 4:00 p.m. EDT. Live audio webcasts will be available on Atreca's website, with replays archived for 90 days.
Atreca, Inc. (NASDAQ: BCEL) reported its Q3 2020 financial results, highlighting ongoing patient enrollment in its Phase 1b trial of ATRC-101. As of September 30, 2020, the company had $259.5 million in cash and cash equivalents. Research and development expenses were $16.8 million, contributing to a net loss of $22.9 million, or $0.66 per share. The company is expanding its clinical trials with plans for combination studies in 2021 and expects to report initial trial data in the first half of 2021.
FAQ
What is the current stock price of ATRECA A (BCEL)?
What is the market cap of ATRECA A (BCEL)?
What is Atreca Inc's primary focus?
What technology does Atreca use for its research?
What is APN-497444?
Why did Atreca suspend the development of ATRC-101?
What partnerships has Atreca established?
What recent corporate actions has Atreca taken?
Who is the CEO of Atreca?
How does Atreca's discovery platform benefit oncology research?
What opportunities are there to work at Atreca?
Where can I find the latest financial results of Atreca?
